Advertisement

Prehypertension and Cardiometabolic Syndrome

  • Reuven Zimlichman
  • Stevo Julius
  • Giuseppe Mancia

Table of contents

  1. Front Matter
    Pages i-xii
  2. Epidemiology and Statistics

    1. Front Matter
      Pages 1-1
    2. Mieczysław Litwin, Janusz Feber, Zbigniew Kułaga
      Pages 3-16
    3. Reuven Zimlichman, Stevo Julius, Giuseppe Mancia
      Pages 17-26
    4. Katarzyna Stolarz-Skrzypek, Danuta Czarnecka
      Pages 27-36
    5. Michael Doumas, Niki Katsiki, Dimitri P. Mikhailidis
      Pages 37-55
    6. Sadi Gulec, Cetin Erol
      Pages 67-77
    7. Andrzej Januszewicz, Aleksander Prejbisz
      Pages 79-98
  3. Organ Damage in Prehypertension

    1. Front Matter
      Pages 99-99
    2. Stéphane Laurent, Pedro Guimarães Cunha
      Pages 101-126
    3. Charalambos Vlachopoulos, Dimitrios Terentes-Printzios, Dimitrios Tousoulis
      Pages 127-136
    4. Thomas Weber, Siegfried Wassertheurer, Bernhard Hametner, Brigitte Kupka, Kai Mortensen
      Pages 137-147
    5. Hermann Haller, Anna Bertram, Klaus Stahl, Jan Menne
      Pages 149-157
    6. Cesare Cuspidi, Marijana Tadic, Guido Grassi
      Pages 159-170
    7. Peter W. de Leeuw, Barry van Varik, Daan J. L. van Twist, Abraham A. Kroon
      Pages 171-182
    8. Damiano Rizzoni, Carolina De Ciuceis, Enzo Porteri, Enrico Agabiti-Rosei, Claudia Agabiti-Rosei
      Pages 183-196
    9. Jonathan Owen, Stephen Morse, Angela McLean, Efrain Reisin
      Pages 197-229
    10. Alexander H. Kirsch, Alexander R. Rosenkranz
      Pages 231-240
    11. Celine Dreyfuss-Tubiana, Michel E. Safar, Jacques Blacher
      Pages 241-249
    12. Enrico Agabiti-Rosei, Anna Paini, Massimo Salvetti
      Pages 251-256
    13. James D. H. Goodman, Ian B. Wilkinson, Carmel M. McEniery
      Pages 257-270
    14. Reza Aghamohammadzadeh, Anthony M. Heagerty
      Pages 271-288
  4. Alteration of Cardiovascular Control Systems

    1. Front Matter
      Pages 289-289
    2. Stefano Taddei, Rosa Maria Bruno, Stefano Masi
      Pages 291-306
    3. Elena Kaschina, Thomas Unger
      Pages 307-318
    4. Paolo Palatini
      Pages 319-339
    5. Stevo Julius
      Pages 341-348
    6. Gino Seravalle, Dagmara Hering, Guido Grassi, Krzysztof Narkiewicz
      Pages 349-360
  5. Risk Assessment in Prehypertension

    1. Front Matter
      Pages 361-361
    2. Raimund Erbel, Nils Lehmann, Andreas Stang, Sofia Churzidse, Susanne Moebus, Karl-Heinz Jöckel
      Pages 363-381
    3. G. Seravalle, G. Grassi, Giuseppe Mancia
      Pages 383-394
    4. Gianfranco Parati, Juan Eugenio Ochoa
      Pages 395-417
    5. Angeliki Ntineri, Anastasios Kollias, George S. Stergiou
      Pages 419-435
    6. Uday M. Jadhav, Onkar C. Swami
      Pages 437-449
    7. Giacomo Pucci, Gianpaolo Reboldi, Fabio Angeli, Dario Turturiello, Paolo Verdecchia
      Pages 471-491
    8. Arnljot Flaa, Morten Rostrup, Sverre E. Kjeldsen, Ivar Eide
      Pages 493-525
  6. End Organ Damage in Prehypertension

    1. Front Matter
      Pages 527-527
    2. Ana Jelaković, Živka Dika, Vesna Herceg-Čavrak, Mario Laganović, Dragan Lović, Bojan Jelaković
      Pages 529-549
  7. Clinical Studies in Prehypertension

  8. Management of Prehypertension

    1. Front Matter
      Pages 583-583
    2. Alan C. Cameron, Giacomo Rossitto, Ninian N. Lang, Rhian M. Touyz
      Pages 585-605
    3. Agnieszka Olszanecka, Danuta Czarnecka
      Pages 607-627
    4. Flávio Danni Fuchs, Sandra Costa Fuchs
      Pages 643-656
    5. Pavel Hamet, Mounsif Haloui, Johanne Tremblay
      Pages 657-675
    6. Jana Brguljan, Giuseppe Ambrosio
      Pages 677-689

About this book

Introduction

This book sheds new light on the management of patients with borderline cardiovascular risk factors in order to prevent their progression to end organ damage. The book stimulates discussion of this poorly understood condition and lays the groundwork for developing recommendations and guidelines.

While the diagnostic and therapeutic approach to full-blown diabetes, hypertension, dyslipidemia and obesity is well defined, there is still a lack of clear understanding and guidelines as far as patients with borderline conditions – especially when multiple – are concerned. Moreover, end-organ damage depends on several factors, including genetic factors, making it difficult to predict its extent. As such, the gradual transition from a healthy subject to one with functional hemodynamic changes, and then one with structurally asymptomatic changes and lastly to overt disease needs further investigation.

In order to address these knowledge gaps, the book covers a broad variety of topics, making it a valuable tool for identifying which asymptomatic subjects could profit from being appropriately screened and at what stage. Furthermore it offers insights into better treating these patients to prevent their progression to overt disease. The book appeals to cardiologists, primary care physicians and all those healthcare professional looking to optimize the management of these complex and often undiagnosed cases.

Keywords

prehypertension high normal blood pressure cardio-metabolic syndrome end-organ damage arterial stiffness hemodynamics multiple cardiovascular risk factors diabetes dyslipidemia neurogenic pre-hypertension Obesity chronic kidney disesase subclinical arteriosclerosis CHINON study PREVERT study THROPHY study antihypertensive drugs metabolic risk factors renal organ damage

Editors and affiliations

  • Reuven Zimlichman
    • 1
  • Stevo Julius
    • 2
  • Giuseppe Mancia
    • 3
  1. 1.Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael
  2. 2.Department of Internal MedicineUniversity of MichiganAnn ArborUSA
  3. 3.Emeritus Professor of MedicineUniversity of Milano-BicoccaMilanItaly

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-319-75310-2
  • Copyright Information Springer International Publishing AG, part of Springer Nature 2019
  • Publisher Name Springer, Cham
  • eBook Packages Medicine
  • Print ISBN 978-3-319-75309-6
  • Online ISBN 978-3-319-75310-2
  • Series Print ISSN 2366-4606
  • Series Online ISSN 2366-4614
  • Buy this book on publisher's site
Industry Sectors
Pharma
Health & Hospitals
Biotechnology